Transaction overview
PLD, a private label pharmaceutical manufacturer based in the United States, acquired Aaron Industries on January 1, 2013. The deal, though its financial terms were undisclosed, resulted in PLD owning 100% of Aaron Industries, a company that specializes in manufacturing private label pharmaceutical and first-aid products. Prior to the acquisition, Aaron Industries had been controlled by Stephens Capital Partners (SCP) since 2010.
Deal structure and financing
Details about the equity and debt components of this transaction are not publicly disclosed. However, it is known that SCP rolled a majority stake in Aaron Industries into PLD, becoming the first non-family shareholder and joining the board alongside the Singer family, which retained full control over PLD prior to the merger. The combined company became the second-largest provider of store-branded pharmaceutical products to U.S. retailers following the acquisition.
Strategic context
PLD's acquisition of Aaron Industries was driven by a strategic intent to diversify its product line and expand its presence in the private label pharmaceutical market, particularly into liquid-based formulations that complemented PLD’s existing solid-dose offerings. This move also helped PLD establish itself as a significant player in an increasingly competitive landscape dominated by larger players like Teva Pharmaceuticals.
Aaron Industries’ rationale for divesting was primarily to consolidate under the leadership and financial support of SCP, thereby accelerating growth and enhancing operational efficiency through integration with PLD’s broader manufacturing capabilities and distribution network. The transaction solidified SCP's role as a strategic investor in PLD’s business model and expansion plans.
Regulatory path
The acquisition did not require any specific regulatory approvals or antitrust remedies given the nature of the deal and the involved market sizes. However, standard regulatory filings were likely made with relevant U.S. agencies, such as those under the Hart-Scott-Rodino Antitrust Improvements Act (HSR) if the transaction crossed the reporting threshold for mandatory filing requirements. Given PLD’s focus on private label pharmaceuticals, no significant competition concerns arose that would necessitate additional scrutiny or remedial actions from regulators in the United States.